You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Susceptibility testing results (CLSI method) for Cryptococcus neoformans isolates from patients, with subsequent clinical outcomes after 10 weeks of antifungal therapy

From: Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis

Initial treatment a and outcome b No of patients/strains No. of strains not susceptible to anti-fungal agent c
AMB FCZ
AMB + 5FC
Cure    
Failure    
Death 1   1
AMB + FCZ
Cure 7 1 1
Failure 12 4 5
Death 4   1
AMB alone
Cure 11   
Failure 4   3
Death 2 2  
FCZ alone
Cure 3 1  
Failure 1   
Death 1   1
  1. Abbreviations: 5FC flucytosine, AMB amphotericin B, FCZ fluconazole.
  2. aThe 46 patients were divided into 4 groups based on their initial anti-fungal treatment regimen used during the first 2 weeks. Thereafter, all patients received fluconazole (400–600 mg daily for 8 weeks at least then 200 mg daily).
  3. bTherapeutic cure was defined as improvement or disappearance of symptoms, negative clinical findings and the cerebro-spinal fluid culture was sterile after 10 weeks of anti-fungal therapy. Therapeutic failure was associated with the persistence of symptoms or cerebro-spinal fluid culture still yielding C. neoformans after 10 weeks of anti-fungal therapy. Death was due to any cause before the end of 10 weeks of anti-fungal therapy.
  4. cThe interpretative criteria for susceptibility to fluconazole were those published by the CLSI [7]. The criteria for susceptibility to amphotericin B were those proposed by Nguyen and Yu [15].